China SXT Pharmaceuticals, Inc. (SXTC)
USD 2.28
(2.7%)
USD 2.28
(2.7%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 2.64 Million USD | -29.53% |
| 2023 | 3.75 Million USD | 83.58% |
| 2022 | 2.04 Million USD | 4613.57% |
| 2021 | 43.41 Thousand USD | -99.35% |
| 2020 | 6.72 Million USD | 2474.69% |
| 2019 | 261.15 Thousand USD | -32.19% |
| 2018 | 385.12 Thousand USD | 27.45% |
| 2017 | 302.16 Thousand USD | -36.95% |
| 2016 | 479.22 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q4 | 2.64 Million USD | -23.47% |
| 2024 Q2 | 3.15 Million USD | -10.38% |
| 2024 FY | 2.64 Million USD | -29.53% |
| 2024 Q3 | 3.45 Million USD | 9.78% |
| 2024 Q1 | 3.51 Million USD | -6.41% |
| 2023 FY | 3.75 Million USD | 83.58% |
| 2023 Q2 | 1.2 Million USD | 0.0% |
| 2023 Q3 | 8.9 Million USD | 638.11% |
| 2023 Q1 | 1.2 Million USD | -41.06% |
| 2023 Q4 | 3.75 Million USD | -57.8% |
| 2022 Q3 | 10.74 Million USD | 44580.36% |
| 2022 FY | 2.04 Million USD | 4613.57% |
| 2022 Q2 | 24.04 Thousand USD | -98.88% |
| 2022 Q4 | 2.04 Million USD | -80.95% |
| 2022 Q1 | 2.14 Million USD | 4832.95% |
| 2021 Q2 | 60.97 Thousand USD | 0.0% |
| 2021 FY | 43.41 Thousand USD | -99.35% |
| 2021 Q3 | 12.19 Million USD | 19896.51% |
| 2021 Q1 | 60.97 Thousand USD | -99.09% |
| 2021 Q4 | 43.41 Thousand USD | -99.64% |
| 2020 FY | 6.72 Million USD | 2474.69% |
| 2020 Q2 | 5.91 Million USD | -23.67% |
| 2020 Q4 | 6.72 Million USD | 0.0% |
| 2020 Q3 | 6.72 Million USD | 13.67% |
| 2020 Q1 | 7.75 Million USD | 2867.76% |
| 2019 Q1 | 380.33 Thousand USD | -1.24% |
| 2019 Q4 | 261.15 Thousand USD | -90.62% |
| 2019 Q3 | 2.78 Million USD | 1346.03% |
| 2019 Q2 | 192.61 Thousand USD | -49.36% |
| 2019 FY | 261.15 Thousand USD | -32.19% |
| 2018 Q1 | - USD | -100.0% |
| 2018 Q3 | 304.21 Thousand USD | 0.0% |
| 2018 Q4 | 385.12 Thousand USD | 26.6% |
| 2018 FY | 385.12 Thousand USD | 27.45% |
| 2017 Q4 | 302.16 Thousand USD | 0.0% |
| 2017 FY | 302.16 Thousand USD | -36.95% |
| 2016 FY | 479.22 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.511% |
| Theratechnologies Inc. | 58.96 Million USD | 95.51% |
| Safety Shot Inc | 1.54 Million USD | -70.917% |
| Cosmos Health Inc. | 12.42 Million USD | 78.691% |
| Cronos Group Inc. | 2.53 Million USD | -4.233% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 99.63% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 92.711% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 97.782% |
| Universe Pharmaceuticals INC | 5.48 Million USD | 51.71% |
| ProPhase Labs, Inc. | 21.38 Million USD | 87.617% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -335.437% |
| Dynavax Technologies Corporation | 256.91 Million USD | 98.97% |
| Radius Health, Inc. | 365.31 Million USD | 99.275% |
| Alvotech | 1.07 Billion USD | 99.754% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -302.529% |
| Alpha Teknova, Inc. | 30.45 Million USD | 91.308% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 84.37% |
| SCYNEXIS, Inc. | 15.08 Million USD | 82.444% |
| Harrow Health, Inc. | 190.5 Million USD | 98.61% |
| Biofrontera Inc. | 5.39 Million USD | 50.964% |
| DURECT Corporation | 20.74 Million USD | 87.239% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 93.625% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 99.16% |
| OptiNose, Inc. | 131.74 Million USD | 97.991% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -125.698% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 97.321% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 85.634% |
| SIGA Technologies, Inc. | 1.46 Million USD | -80.836% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 97.969% |
| Shineco, Inc. | 29.65 Million USD | 91.073% |
| Phibro Animal Health Corporation | 525.45 Million USD | 99.496% |
| Procaps Group S.A. | 285.93 Million USD | 99.074% |
| TherapeuticsMD, Inc. | 8 Million USD | 66.927% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -4326.664% |
| Viatris Inc. | 18.12 Billion USD | 99.985% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -302.529% |
| Rockwell Medical, Inc. | 13.43 Million USD | 80.3% |
| Incannex Healthcare Limited | 373 Thousand USD | -609.773% |
| Aytu BioPharma, Inc. | 15.12 Million USD | 82.501% |
| Tilray Brands, Inc. | 387.31 Million USD | 99.316% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 99.607% |
| PetIQ, Inc. | 468.3 Million USD | 99.435% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.382% |
| Journey Medical Corporation | 17.73 Million USD | 85.068% |
| Alimera Sciences, Inc. | 67.39 Million USD | 96.072% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | 68.013% |
| Assertio Holdings, Inc. | 40.91 Million USD | 93.529% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -143.401% |
| Embecta Corp. | 1.63 Billion USD | 99.838% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -156.259% |
| Procaps Group, S.A. | 285.93 Million USD | 99.074% |
| PainReform Ltd. | 86 Thousand USD | -2978.436% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 92.518% |
| Hempacco Co., Inc. | 13.72 Million USD | 80.71% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 99.548% |
| Alvotech | 1.07 Billion USD | 99.754% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 99.571% |
| Kamada Ltd. | 8.74 Million USD | 69.74% |
| Indivior PLC | 281.6 Million USD | 99.06% |
| Currenc Group, Inc. | 31.94 Million USD | 91.712% |
| Evoke Pharma, Inc. | 5 Million USD | 47.051% |
| Flora Growth Corp. | 3.67 Million USD | 27.902% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -156.259% |
| Evolus, Inc. | 126.54 Million USD | 97.908% |
| HUTCHMED (China) Limited | 86.13 Million USD | 96.926% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 99.575% |
| Akanda Corp. | 3.99 Million USD | 33.794% |